Drug intelligence / Profile preview

Methyl-beta-cyclodextrin

Development stage: Preclinical
Lead developer: SolAeroMed
Administration: Intravenous, Oral

Overview

Methyl-beta-cyclodextrin is a methylated derivative of β-cyclodextrin, used primarily as an excipient to enhance the solubility and bioavailability of poorly water-soluble drugs. It is known for its ability to form inclusion complexes, which can solubilize hydrophobic substances, and is used in drug delivery systems. Methyl-beta-cyclodextrin also has cholesterol-removing properties, making it useful for applications such as disrupting lipid rafts and modulating membrane dynamics. Additionally, it acts as an actin depolymerizer, affecting cellular processes like focal adhesion and intracellular drug accumulation.

Other names: Methyl-β-cyclodextrinMethyl-beta-cyclodextrinMBCMethyl-β-cyclodextrineMβCDMe-β-CDBETACDRM-β-CD-o

Targets

F-actin (Filamentous actin)

Beyond the preview

Go deeper on Methyl-beta-cyclodextrin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Methyl-beta-cyclodextrin.

Explore the full profile